Adverse Factors and the Role of Cisplatin and Vinca Alkaloids for Hearing Impairment in Childhood Cancer Patients and Survivors

다국어 초록 (Multilingual Abstract)

Background: Although combined chemotherapy has increased survival rates among children with cancer, such treatments can induce sensorineural hearing loss. Therefore, we aimed to identify risk factors for hearing impairments in patients with childhood cancer.
Methods: Audiograms were obtained from 115 patients with childhood cancer and survivors (age ＜20 years). Pure tone audiometry (PTA) was performed at octave intervals within the range of 250-8000 Hz. We evaluated clinical risk factors associated with hearing impairments. Hearing loss was evaluated based on the maximal decibel (dB) loss in any frequency for each ear (RAmax or LAmax) and weighted mean dB loss for specific frequencies (RAavg or LAavg).
Results: Forty percent of patients (N=46) exhibited hearing loss ＞20 dB based on the weighted mean value in either ear. Severe hearing impairments were observed in 56% of patients with brain tumors. Although cisplatin or vinca alkaloids were significant risk factors for hearing impairment, the use of both cisplatin and vinca alkaloids exhibited the highest odds ratio for hearing impairment (P＜0.001, ＜0.001 for R/LAmax; P=0.099, 0.039 for R/LAavg). Multivariate analysis revealed that the use of both cisplatin and vinca alkaloids was an independent risk factor for hearing impairment based on RAmax, LAmax, and LAavg (P＜0.001, ＜0.001, 0.039, respectively).
Conclusion: Our findings indicate that cisplatin and vinca alkaloids exert an additive effect on the risk of hearing impairment in survivors of childhood cancer. Further prospective studies are thus required to determine the most effective chemotherapeutic regimen for reducing ototoxicity.

참고문헌 (Reference)

1 Nazir HF, "Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: Frequent autonomic and more severe cranial nerve involvement" 64 : 2017

2 Brinkman TM, "Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study" 121 : 4053-4061, 2015

3 Robison LL, "Survivors of childhood and adolescent cancer: life-long risks and responsibilities" 14 : 61-70, 2014

4 Ding D, "Review: ototoxic characteristics of platinum antitumor drugs" 295 : 1851-1867, 2012

5 Bhandare N, "Radiation therapy and hearing loss" 76 : S50-S57, 2010

6 Yun C, "Prevalence and social risk factors for hearing impairment in chinese children-a national survey" 14 : 2017

7 Chang KW, "Practical grading system for evaluating cisplatin ototoxicity in children" 28 : 1788-1795, 2010

8 van As JW, "Platinum-induced hearing loss after treatment for childhood cancer" CD010181-, 2016

9 Ruggiero A, "Platinum compounds in children with cancer: toxicity and clinical management" 24 : 1007-1019, 2013

10 Landier W, "Ototoxicity and cancer therapy" 122 : 1647-1658, 2016

11 Rowe LS, "Optimizing the benefit of CNS radiation therapy in the pediatric population-part 1: understanding and managing acute and late toxicities" 31 : 182-188, 2017

12 한정우, "Increasing and Worsening Late Effects in Childhood Cancer Survivors during Follow-up" 대한의학회 28 (28): 755-762, 2013

13 Bass JK, "Hearing loss in patients who received cranial radiation therapy for childhood cancer" 34 : 1248-1255, 2016

14 Hirose Y, "Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line" 12 : 719-728, 2011

15 Stevens G, "Global and regional hearing impairment prevalence: an analysis of 42 studies in 29 countries" 23 : 146-152, 2013

16 Park HJ, "Establishment of Korean childhood cancer survivor cohort and long-term follow-up system" 14 : 1-42, 2007

17 Han JW, "Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention" 20 : 1170-1177, 2009

18 Lee JW, "Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers" 38 : 423-431, 2016

19 Hudson MM, "Clinical ascertainment of health outcomes among adults treated for childhood cancer" 309 : 2371-2381, 2013

20 Yasui N, "Cisplatin-induced hearing loss: the need for a long-term evaluating system" 36 : e241-e245, 2014

21 Ho GY, "Cisplatin versus carboplatin:comparative review of therapeutic management in solid malignancies" 102 : 37-46, 2016

22 Mujica-Mota M, "Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review" 35 : 1662-1668, 2013

23 Grewal S, "Auditory late effects of childhood cancer therapy:a report from the Children's Oncology Group" 125 : e938-e950, 2010